NEUROTRANSMITTER MEASURES IN THE CEREBROSPINAL FLUID OF PATIENTS WITH ALZHEIMER'S DISEASE: A REVIEW

Dubravka Svob Strac, Dorotea Muck-Seler & Nela Pivac
Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia

received: 4.9.2014; revised: 27.12.2014; accepted: 7.1.2015

SUMMARY

Background: Alzheimer's disease (AD) is a severe neurodegenerative disorder characterized by progressive cognitive and functional decline, as well as a variety of neuropsychiatric and psychological symptoms and behavioral dysfunctions. Various studies proposed the role of different neurotransmitter systems not only in AD-related cognitive, but also psychotic symptoms and behavioral and emotional deficits. Due to the close proximity, pathological neurochemical changes in brain occurring in AD are likely to be reflected in the cerebrospinal fluid (CSF). The purpose of this review is to provide a summary of the CSF neurotransmitter correlates of AD in order to get further insights into the potential role of altered neurotransmitters in the pathophysiology of AD and to offer novel AD biomarkers.

Methods: PubMed and MEDLINE databases were searched for English-language articles by using "Alzheimer's disease", "CSF" and "neurotransmitter" as primary terms. No time or article type constraints were applied. Moreover, the lists of references were searched manually for additional articles.

Results: Changes in various correlates of cholinergic, monoaminergic and amino acid neurotransmitter systems, as well as neuropeptides, have been observed in CSF of AD patients. However, as the results of these studies have been controversial, the importance of CSF neurotransmitter parameters as potential biomarkers in AD remains quite unclear. The observed discrepancies could be bypassed by implementation of new sensitive methods, such as novel proteomics approaches that include protein separation techniques, mass spectrometry and targeted multiplex panels of specific analytes.

Conclusion: Although no individual CSF neurotransmitter correlate was demonstrated as suitable biomarker of AD, a combined profile of several CSF neurochemical parameters might show enhanced sensitivity and specificity and thus contribute to earlier and more accurate diagnosis of AD, crucial for application of effective treatments.

Key words: Alzheimer's disease - biomarkers - CSF - neurotransmitters – review

INTRODUCTION

Alzheimer's disease (AD) is a severe age-related neurodegenerative disorder characterized by a progressive cognitive and functional decline, as well as a variety of neuropsychiatric and psychological symptoms and behavioral dysfunctions (Wuwongse et al. 2010). The major pathological features of AD are progressive loss of basal forebrain cholinergic neurons, as well as accumulation of extracellular senile plaques formed mainly of the amyloid-β peptide (Aβ), and intracellular neurofibrillary tangles (NFT), which contain hyperphosphorylated tau (P-tau) (Armstrong et al. 2013, Ubhi & Masliah 2013). It has been suggested that AD is a complex multifactorial disorder, with many proposed theories as to the cause of AD, including those based on aging, degeneration of anatomical pathways, environmental factors, genetic factors, mitochondrial dysfunction, vascular factors, immune system dysfunction, and infectious agents (Armstrong et al. 2013). However, despite extensive and long-lasting research, there is still no cure, no prevention, and only limited symptomatic treatment options, in part due to the current inability of early AD diagnosis.

Although AD primarily affects brain regions involved in learning and memory, such as the neocortex and the hippocampus (Rodriguez et al. 2012), in addition to its primary effects on cognition, “noncognitive” neuropsychiatric symptoms are present in great majority of AD patients (Lee & Lyketsos 2003, Ged a et al. 2013). The mood and behavioral disturbances in AD, including agitation, anxiety, depression, apathy, psychosis, as well as sleep or appetite impairments (Lyketsos et al. 2000, Geda et al. 2013), have various adverse consequences for patients, such as greater impairment in the activities of daily living (Lyketsos et al. 1997), more rapid cognitive decline (Stern et al. 1997), worse quality of life (Gonzales-Salvador et al. 2000), earlier institutionalization (Steele et al. 1990), as well as greater caregiver depression (Gonzales-Salvador et al. 1999). The prevalence of these behavioral and emotional symptoms has been estimated to be 3 to 4 times higher in AD patients than in aged persons without dementia (Lyketsos & Olin 2002).

Hence, is not surprising that although current AD pharmacotherapy focuses mainly on impairment of cholinergic and glutamatergic systems (Chu et al. 2012), in addition to acetylcholine esterase inhibitors (donepezil, rivastigmine, galantamine) and cognitive enhancers (memantine), a variety of drugs is used in order to relieve behavioral and psychological symptoms of dementia (BPSD) (Rojas-Fernandez et al. 2001, Amano et
al. 2009, Gauthier et al. 2010). These other drugs used in the therapy of AD patients with BPSD include anti-psychotics, antidepressants (selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors), anti-insomnia drugs, anxiolytic as well as anticonvulsant drugs (Aupperle 2006, Henry et al. 2011, Yeh & Ouyang 2012).

A vast number of experimental studies suggested progressive loss of neuronal synapses and consequent disturbance of different neurotransmitter pathways in AD (Reinikainen et al. 1990, Francis et al. 2010, Xu et al. 2012). Various studies proposed the role of different neurotransmitters (including their transporters and receptors), such as serotonin, noradrenaline, acetylcholine, dopamine and N-methyl-D-aspartate, as crucial neuromodulators, whose pathological alterations contribute to cognitive impairments and/or deterioration in AD (Kevin et al. 2011, Xu et al. 2012). However, these neurotransmitter systems are involved not only in AD-related cognitive, but also behavioral deficits (Lanari et al. 2006, Rodriguez et al. 2012, Vermeiren et al. 2014a,b). Namely, research suggests that altered activities and imbalance of cholinergic, dopaminergic, serotonergic, (nor)adrenergic, as well as amino acid neurotransmitter systems are particularly involved in the etiopathogenesis of BPSD (Herrmann et al. 2004, Garcia-Alloza et al. 2005, 2006, Lanctôt et al. 2001, 2007, Chen et al. 2011, Pinto et al. 2011, Vermeiren et al. 2013).

Due to close proximity of brain parenchyma and cerebrospinal fluid (CSF), pathological changes in brain occurring in AD are likely to be reflected in the CSF (Raedler & Wiedemann 2006). Hence, as in the case of other CSF biomarkers (tau, P-tau and Aβ42), CSF levels of different neurotransmitters might be also correlated with neurochemical alternations in AD brain (Beal & Growdon 1986), cognitive decline (Kawakatsu et al. 1990, Kester et al. 2009), as well as with noncognitive AD symptoms (Roe et al. 2013, Vermeiren et al. 2013). The purpose of this review is to provide a summary of previous findings regarding CSF neurotransmitter correlates of AD in order to get further insights into their potential role in improvement of AD current biomarkers.

METHODS

To perform a comprehensive review of the literature focusing on the studies of CSF neurotransmitters in AD, an electronic search of English-language articles was conducted using PubMed and MEDLINE. The primary search with terms “Alzheimer’s disease”, “CSF” and “neurotransmitter” yielded initially 262 references, 254 of them in English. No time or article type constraints were applied. Relevant scientific literature including original research articles, reviews, and other articles of interest were systematically reviewed, and the most important data was extracted. Moreover, the lists of references were searched manually for additional articles. Finally, out of 133 citations, 97 references specifically regarding CSF neurotransmitters in AD were selected and included in this review providing a summary of these findings as well as their critical appraisal.

ACETYLCOLINE

Specific degeneration of cholinergic neurons, down-regulation of choline acetyltransferase, the enzyme responsible for the synthesis of acetylcholine (ACh), as well as reduced choline uptake and ACh release, resulting in severe deficits of cholinergic neurotransmitter system function, have been observed in AD patients (Francis et al. 1999, Schliebs & Arendt 2011). Cholinergic replacement, using acetylcholine esterase inhibitors, which improves cognitive functions, is one of the few available and effective strategies for the treatment of AD. Ionotropic nicotinic (nAChR) and metabotropic muscarinic (mAChR) acetylcholine receptors, which both mediate acetylcholine-induced neurotransmission, have been also affected in AD (Jiang et al. 2014, Lombardo & Moskos 2014). It has been suggested that observed reduction in the number of AChR occurs in the early stages of the pathological process and is closely associated with primary histopathological changes in AD, such as amyloid plaques and neurofibrillary tangles (Kihara & Shimohama 2004).

These findings suggest that peripheral markers of central cholinergic activity may be also useful in the diagnosis of this disease. ACh concentrations in CSF of AD patients were found to be significantly lower than in control subjects, while ACh deficit correlated positively with cognitive impairment (Davis et al. 1985, Tohgi et al. 1994, Jia et al. 2004). Despite of ACh reductions observed in CSF of AD patients, some authors argued whether determination of ACh levels in CSF is suitable for diagnostic purposes of AD due to methodological limitations (Frolich et al. 1998). Increased concentrations of choline in CSF of AD patients have been also demonstrated, suggesting a disturbance in utilization of choline for ACh synthesis (Ikeda et al. 1990). However, some studies observed no differences in CSF choline levels between AD patients and normal controls (Tohgi et al. 1994, Jia et al. 2004).

Reduced CSF activity of acetylcholinesterase (AChE), nonspecific cholinesterase (nsChE) or butyrylcholinesterase (BuChE) has been reported in some (Appleyard et al. 1987, Atack et al. 1988, Kaye et al. 1988, Sirvio et al. 1989, Kawakatsu et al. 1990, Appleyard & McDonald 1992) but not in all AD studies (Marquis et al. 1985, Zubenko et al. 1986, Elble et al. 1987, Huff et al. 1989, Markstein et al. 2008). It has been demonstrated that AChE levels in CSF of AD patients closely mirror the in vivo brain AChE levels (Darreh-Shori et al. 2008), and that low AChE activities in CSF are associated with degrees of dementia as well as the Alzheimer-related symptoms of dyspraxia and dysphasia (Wester et al. 1988). Moreover, some authors reported that AChE species differ in their responses to disease and their interactions with Aβ and P-tau...
(Garcia-Ayllón et al. 2011). Studies addressing AChE - amyloid interrelationships indicated that AChE may participate in the pathological feedback loop between presenilin-1 (PS1) and Aβ (Silveyra et al. 2012), by increasing PS1 levels and inhibiting the γ-secretase activity (Campanari et al. 2014).

It has been hypothesized that CSF butyrylcholinesterase levels vary inversely with butyrylcholinesterase in cortical amyloid plaques and that low butyrylcholinesterase levels in AD patient's CSF could possibly predict extensive incorporation in neuritic plaques, increased neurotoxicity and greater central neurodegeneration (Darreh-Shori et al. 2006). The studies investigating the interrelationships between apolipoprotein E (ApoE) and butyrylcholinesterase levels, and pathological markers of AD in vivo, suggested that abnormally high levels of ApoE might be involved in the early cholinergic deficit in the AD brain, and that through modulation of cholinesterases activities may disturb the acetylcholine-dependent activity of neurons and glial cells (Darreh-Shori et al. 2011).

Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity (Arendt et al. 1984), as well as elevated ratio of acetylcholinesterase to nonspecific cholinesterase activities in CSF was observed in patients with AD (Appleyard et al. 1987). Some studies have also shown altered acetylcholinesterase and butyrylcholinesterase glycosylation in CSF, very specific for AD (Saez-Valero et al. 1997, 2000, Saez-Valero & Small 2001). However, subsequent results suggested that observed increased CSF levels of acetylcholinesterase and butyrylcholinesterase glycosylated forms are not likely to represent early markers of AD, although they may be useful as markers of disease progression (Saez-Valero et al. 2003).

MONOAMINE NEUROTRANSMITTERS

It has been suggested that CSF cholinergic deficits in AD are more often associated with cognitive decline that the deficits of other monoamines (Kawakatsu et al. 1990). However, the first detailed studies on CSF chemistry in relation to AD were reports from late 1960s and early 1970s about reduced CSF monoamine metabolite concentrations, suggesting a breakdown of these neurotransmitter systems in the deteriorating brain (Zetterberg & Blennow 2013). The concentrations of monoamine metabolites homovanilic acid (HVA), dihydroxyphenylacetic acid (DOPAC), and 5-hydroxyindolacetic acid (5-HIAA), as well as monoamine synthesis cofactor biotinperin were found to be significantly decreased in AD (Soinnen et al. 1981, Bareggi et al. 1982, Volicer et al. 1985b, Kay et al. 1986, Zubenko et al. 1986, Pinessi et al. 1987, Kaye et al. 1988a,b, Brane et al. 1989, Kawakatsu et al. 1990, Martignoni et al. 1991, Blennow et al. 1992, Parnetti et al. 1992, Sjogren et al. 1998). AD patients with severe forms of mental deterioration and senile dementia demonstrated most prominent decrease in the CSF levels of HVA and 5-HIAA, which may reflect a decreased turnover of dopamine and serotonin (Soinnen et al. 1981, Bareggi et al. 1982).

However, unaffected (Bareggi et al. 1982, Zimmer et al. 1984, Nybäck et al. 1991, Molchan et al. 1991, Parnetti et al. 1992, Toghi et al. 1992, Sheline et al. 1998, Stuerenberg et al. 2004) or elevated (Volicer et al. 1985b, Zubenko et al. 1986, van der Cammen et al. 2006) levels of HVA and 5-HIAA were also reported in AD. Although some authors found no differences in CSF levels of HVA and 5-HIAA between mild cognitive impairment, depression and AD, they observed elevated HVA levels in AD with depression in comparison to AD without depression, as well as positive correlation of 5-HIAA with Aβ42 and HVA levels in CSF of AD patients (Stuerenberg et al. 2004). In addition to observed changes in the CSF levels of monoamine metabolites, findings of reduced CSF concentrations of neurotransmitters dopamine (Pinessi et al. 1987, Toghi et al. 1992) and serotonin (5-HT), as well as serotonin precursor 5-hydroxytryptophan (5-HTP) (Volicer et al. 1985a) suggested systemic damage of monoaminergic neurons in AD. Moreover, some authors reported abnormal, partially oxidized forms of 5-HT and 5-HTP in CSF of AD patients (Volicer et al. 1985a).

Although lower norepinephrine (NE) levels and degeneration of noradrenergic neurons have been observed in the brain of AD patients, the aging-associated high CSF concentrations of NE are retained in the earlier stages of AD and are significantly higher in the patients with advanced stage of the disease (Elrod et al. 1997, Raskind et al. 1999). However, some studies revealed no changes (Toghi et al. 1992), as well as significant reduction (Martignoni et al. 1991) in CSF NE levels in AD patients. Observed increased CSF levels of NE precursor dihydroxyphenylacetic acid (DOPA) in older and AD patients than in young subjects following alpha-2 adrenoreceptor blockade with yohimbine suggested particularly prominent compensatory activation of remaining CNS noradrenergic neurons (Raskind et al. 1999). CSF levels of NE metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) were shown to be unchanged (Volicer et al. 1985b, Nybäck et al. 1991, Molchan et al. 1991, Parnetti et al. 1992, Blennow et al. 1992), lower (Sjogren et al. 1998) or higher (Brane et al. 1989, Toghi et al. 1992) in patients with AD then in control subjects, and inversely correlated with cognitive function (Gibson et al. 1985, Sheline et al. 1998). Higher CSF levels of epinephrine (EPI) were also found in AD and increased further with dementia severity in AD patients (Peskind et al. 1998).

AMINO-ACID NEUROTRANSMITTERS

Glutamate, as major fast excitatory neurotransmitter in the brain, is involved in almost all CNS functions; however it plays especially important role in neuronal plasticity underlying learning and memory. The variety of evidence suggests that glutamatergic system and particularly
### Table 1. Changes in the main components of different neurotransmitter systems observed in the CSF of AD patients

<table>
<thead>
<tr>
<th>Neurotransmitter System component</th>
<th>Change in AD</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylcholine decrease</td>
<td>Davis et al. 1985, Tohgi et al. 1994, Jia et al. 2004</td>
<td></td>
</tr>
<tr>
<td>Choline increase</td>
<td>Ikeda et al. 1990</td>
<td></td>
</tr>
<tr>
<td>Nonspecific cholinesterase no changes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopterin increase</td>
<td>Volicer et al. 1985b, Zubenko et al. 1986, van der Cammen et al. 2006</td>
<td></td>
</tr>
<tr>
<td>Dopamine decrease</td>
<td>Pinessi et al. 1987, Toghi et al. 1992</td>
<td></td>
</tr>
<tr>
<td>Serotonin (5-HT) decrease</td>
<td>Volicer et al. 1985a</td>
<td></td>
</tr>
<tr>
<td>5-hydroxytryptophan (5-HTP) no change</td>
<td>Bareggi et al. 1982</td>
<td></td>
</tr>
<tr>
<td>Norepinephrine (NE) increase</td>
<td>Elrod et al. 1997, Raskind et al. 1999</td>
<td></td>
</tr>
<tr>
<td>Dihydroxyphenylacetic acid (DOPA) decrease</td>
<td>Martignoni et al. 1991</td>
<td></td>
</tr>
<tr>
<td>3-methoxy-4-hydroxyphenylglycol (MHPG) increase</td>
<td>Brane et al. 1989, Toghi et al. 1992</td>
<td></td>
</tr>
<tr>
<td>decrease</td>
<td>Sjogren et al. 1998</td>
<td></td>
</tr>
<tr>
<td>Epinephrine (EPI) increase</td>
<td>Peskind et al. 1998</td>
<td></td>
</tr>
<tr>
<td>Gamma-aminobutyric acid (GABA) increase</td>
<td>Samakashvili et al. 2011</td>
<td></td>
</tr>
<tr>
<td>decrease</td>
<td>Enna et al. 1977, Kuroda 1983, Zimmer et al. 1984</td>
<td></td>
</tr>
<tr>
<td>no change</td>
<td>Bareggi et al. 1982</td>
<td></td>
</tr>
<tr>
<td>Glutamine increase</td>
<td>D’Aniello et al. 2005</td>
<td></td>
</tr>
<tr>
<td>decrease</td>
<td>Smith et al. 1985, Kuiper et al. 1994, 2000</td>
<td></td>
</tr>
<tr>
<td>decrease</td>
<td>Samakashvili et al. 2011</td>
<td></td>
</tr>
<tr>
<td>Glutamate increase</td>
<td>Jimenez-Jimenez et al. 1998, Kaiser et al. 2010</td>
<td></td>
</tr>
<tr>
<td>decrease</td>
<td>Raskind et al. 1986, Kuiper et al. 1994, 2000</td>
<td></td>
</tr>
<tr>
<td>no change</td>
<td>Smith et al. 1985, Ferrarese et al. 2001</td>
<td></td>
</tr>
<tr>
<td>Nitrate decrease</td>
<td>Kuiper et al. 1994, 2000</td>
<td></td>
</tr>
<tr>
<td>no change</td>
<td>Navarro et al. 1996</td>
<td></td>
</tr>
<tr>
<td>Glycine increase</td>
<td>Jimenez-Jimenez et al. 1998</td>
<td></td>
</tr>
<tr>
<td>Asparagine decrease</td>
<td>Jimenez-Jimenez et al. 1998, Samakashvili et al. 2011</td>
<td></td>
</tr>
<tr>
<td>Arginine decrease</td>
<td>Raskind et al. 1986</td>
<td></td>
</tr>
<tr>
<td>Lysine decrease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L-aspartate decrease</td>
<td>D’Aniello et al. 2005</td>
<td></td>
</tr>
<tr>
<td>Somatostatin-like immunoreactivity (sli) no changes</td>
<td>Heilig et al. 1995</td>
<td></td>
</tr>
<tr>
<td>Y-immunoreactivity (NPY-ir) no changes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>decrease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Dubravka Svob Strac, Dorotea Muck-Seler & Nela Pivac: NEUROTRANSMITTER MEASURES IN THE CEREBROSPINAL FLUID OF PATIENTS WITH ALZHEIMER’S DISEASE: A REVIEW** *Psychiatria Danubina, 2015; Vol. 27, No. 1, pp 14–24*
Table 1. Continuous

<table>
<thead>
<tr>
<th>Neurotransmitter System component</th>
<th>Change in AD</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histidine methionine immunoreactivity</td>
<td>no changes</td>
<td>Yasuda et al. 1995</td>
</tr>
<tr>
<td>Histidine valine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histidine methionine 27</td>
<td>increase</td>
<td>Marksteiner et al. 2008</td>
</tr>
<tr>
<td>Vasoactive intestinal peptide (VIP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mature nerve growth factor (NGF)-like immunoreactivity</td>
<td>increase</td>
<td>Rosler et al. 2001</td>
</tr>
<tr>
<td>Substance P-like-immunoreactivity</td>
<td>decrease</td>
<td>Cramer et al. 1985</td>
</tr>
<tr>
<td>Adrenocorticotropic hormone (ACTH)</td>
<td>increase</td>
<td>Heilig et al. 1995</td>
</tr>
<tr>
<td>Delta-sleep-inducing peptide</td>
<td>decrease</td>
<td>Ernst et al. 1987, Edvinsson et al. 1993</td>
</tr>
<tr>
<td>Galanin</td>
<td>decrease</td>
<td>Mazurek et al. 1986, Raskind et al. 1986</td>
</tr>
<tr>
<td>Arginine vasopressin</td>
<td>no change</td>
<td>Jolkkonen et al. 1989</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>no change</td>
<td>Raskind et al. 1986</td>
</tr>
<tr>
<td></td>
<td>no change</td>
<td>Raskind et al. 1986</td>
</tr>
</tbody>
</table>

-ionotropic glutamate N-methyl-D-aspartate (NMDA) receptors play a significant role in synaptic dysfunction and neuronal death, as well as in cognitive deficits in AD (Wenk et al. 2006). Strong support for relevance of interactions between Aβ, glutamate and NMDA receptors in AD is provided by the NMDA receptor antagonist memantine, used clinically in the treatment of this disease (Danszy & Parsons 2012). In CSF of AD patients, observed lower concentration of glutamate correlated with psychological measures (Smith et al. 1985), and was related to the degree of dementia (Ferrarese et al. 2001). However, glutamate was also found to be significantly elevated in the CSF of patients with AD (Jimenez-Jimenez et al. 1998, Kaiser et al. 2010). These findings also suggest that glutamate metabolism is altered in AD and that glutamatergic neurons are not spared in this disorder.

Reduced levels of major inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in CSF were also observed in patients with AD (Enna et al. 1977, Kuroda 1983, Zimmer et al. 1984). Some authors demonstrated that GABA levels decreased with age, however when compared with the age-matched controls, patients with AD showed no changes in GABA concentrations (Bareggi et al. 1982). Although glycine and glutamine in the CSF of AD samples were found to be lower than these measures in control samples (Smith et al. 1985), some authors observed higher CSF glycine levels, as well as lower asparagine levels in AD patients (Jimenez-Jimenez et al. 1998). By using enantioselective procedures, Samakashvili and colleagues investigated D- and L-amino acid contents in CSF samples related to different AD stages and observed lower amounts of L-arginine, L-lysine, L-glutamate and L-asparagine and higher levels of GABA in AD subjects (Samakashvili et al. 2011). Much higher levels of L-glutamine and lower concentrations of L-aspartate, also observed in CSF of AD patients, are suggested to be the consequence of the higher activity of glutamic oxaloacetate transaminase (GOT) that occurs in Alzheimer brain (D’Aniello et al. 2005). As biosynthesis of nitric oxide (NO) is dependent on the L-glutamate, which stimulates nitric oxide synthesis via the NMDA receptor, the findings of decreased levels of L-glutamate and nitrate (nitric oxide degradation product) in CSF of AD patients, suggested that AD is associated with a decrease in nitric oxide CNS production (Kuiper et al. 1994, 2000). In contrast, some results demonstrating no changes in CSF nitrate levels suggested that they are apparently unrelated with the risk of AD (Navarro et al. 1996).

**NEUROPEPTIDES**

Nilsson et al. 2001), as well as reduction in neuropeptide Y-immunoreactivity (NPY-ir) (Martignoni et al. 1992, Edvinsson et al. 1993, Nilsson et al. 2001), has been observed in CSF of patients with AD. The correlations of somatostatin and neuropeptide Y to the clinical signs of AD disorientation and dyspraxia were found and somatostatin showed a significant negative correlation with severity of dementia in AD (Cramer et al. 1985, Strittmatter et al. 1997, Minthon et al. 1997). Measurement of molecular forms of somatostatin in CSF revealed significant loss of somatostatin-14 (SST-14) in AD which was correlated with dementia scores (Strittmatter et al. 1997). These qualitative and quantitative changes in the molecular pattern of somatostatin-like immunoreactivity in AD indicated dysregulated synthesis and/or processing of somatostatin relating to the severity of dementia (Strittmatter et al. 1997). The concentrations of SS-28, peptide derived from preprosomatostatin (prepro-SS), were found to be significantly reduced in AD, while somatostatin-14 levels in AD patients did not differ from those of controls (Yasuda et al. 1995). These results suggested that an altered processing of the prepro-peptides of somatostatin may occur in AD and that these alterations might have a significant role in the pathogenesis of this disease.

Reduced levels of total peptide histidine methionine immunoreactivity and peptide histidine valine, as well as unaltered levels of peptide histidine methionine 27 and vasoactive intestinal peptide (VIP) were observed in AD (Yasuda et al. 1995). On the other hand, mature nerve growth factor (NGF)-like immunoreactivity, but not anti-NGF auto-antibody levels, was found enhanced in AD patients (Marksteiner et al. 2008). Patients with late onset AD (>65 years) showed significantly higher levels of substance P-like-immunoreactivity than patients with early onset (<65 years) and controls (Rosler et al. 2001). Substance P-like-immunoreactivity correlated with somatostatin-like immunoreactivity in AD patients, but was decreased significantly only in late onset AD patients (Cramer et al. 1985). Moreover, CSF concentrations of corticotrophin-releasing hormone (CRH), beta-endorphine, somatostatin (SRIF, somatotropin releasing-inhibiting factor) and adrenocorticotropic hormone (ACTH) were markedly lower, and delta-sleep-inducing peptide was increased in AD patients, while beta-endorphine levels correlated negatively with degree of dementia (May et al. 1987, Suemaru et al. 1991, 1993, Heilig et al. 1995). However, opposite results such as strong reduction in the levels of delta-sleep-inducing peptide (Ernst et al. 1987, Edvinsson et al. 1993), no changes in neuropeptide Y levels (Heilig et al. 1995), as well as unchanged (Pomara et al. 1989, Edvinsson et al. 1993) or even elevated (Banki et al. 1992) CRH levels were also observed in CSF of AD patients. It has been shown that galanin levels increased with the duration of illness in AD patients (Nilsson et al. 2001). The CSF arginine vasopressin concentrations were found unchanged (Jolkkonen et al. 1989) or decreased (Mazurek et al. 1986, Raskind et al. 1986) in patients with AD, while oxytocin and beta-endorphin levels did not differ between patients with AD, normal elderly subjects and normal young subjects (Raskind et al. 1986).

CONCLUSION

A variety of data suggested that coupling of clinical/neurological parameters to different CSF profiles could improve early, accurate diagnosis of AD, which is a key to maximize disease-modifying treatment benefits (Bennett et al. 2010). While CSF tau, P-tau and Aβ have become part of the diagnostic process in clinical routine (Andreasen et al. 2003, Bennett et al. 2010), the importance of other CSF neurochemical parameters as potential biomarkers in AD remains quite unclear. Namely, no individual CSF neurotransmitter correlate was found as suitable biomarker of AD. However, as the results of previous studies suggest that AD pathophysiology involves early changes in functionally connected networks across many brain regions, there is an urgent need for broader biomarker investigations that should lead to better understanding of early disease mechanisms and help diagnose AD in the preclinical and early clinical stages (Shaw et al. 2007, Trushina et al. 2013).

The above reviewed variability regarding CSF neurotransmitter research is probably due to differences in sampling and used methodology. Therefore, in order to discover sensitive and specific biomarkers for AD, standardization of methods (CSF extraction, CSF gradient effects, storage, etc.) is essential for reducing inconsistency and increasing reliability, while consensus protocols of analysis are of critical importance (Cedazo-Minguez & Winblad 2010). Moreover, discrepancies between findings could be bypassed by implementation of new sensitive methods, such as novel proteomics approaches that include protein separation techniques, mass spectroscopy and targeted multiplex panels of specific analytes (Choi et al. 2010, Bennett et al. 2010, Czech et al. 2012, Trushina et al. 2013, Kovac et al. 2014).

The new approaches have already determined a number of candidate combinations, many of them in different neurotransmitter pathways, that could improve on the "core" protein biomarkers tau, P-tau and Aβ. None has been yet validated enough to be included in clinical practice, the combined profiles of several neurochemical markers from CSF might demonstrate enhanced sensitivity and specificity, and thus contribute to earlier and more accurate diagnosis, crucial for successful therapy of both AD cognitive and behavioral symptoms.

Acknowledgements

This work was supported by the Croatian Ministry of Science, Education and Sport (grants no. 098-000000-244, 098-0982522-2455, 098-0982522-2457), Croatian Science Foundation (grant no. 09/16) and CMST COST Action CM1103.

Conflict of interest: None to declare.
References


127. Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, De Deyn PP: Brain region-specific monoaminergic corre-


